InsideTrading SEC Form 4 insider trades
← All clusters
RAPP

Rapport Therapeutics, Inc.

Healthcare Pharmaceutical Preparations Market cap: $1.6B Ticker page → Watch RAPP (just your e-mail) Price alert (just your e-mail)

Limited buying: $22.0M bought (counted up to $5.0M); 7 distinct insiders. Holding it back: largest buyer: Ignelzi Troy A. (CFO), 92% of the dollars.

AI summary RAPP CFO and directors buy $1.66M on open market after Phase 2 readout, followed by $20.36M fund purchase at offering price

57
Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation. <60 · limited buying
+0.2%
Since the cluster formed, vs benchmark (+0.8% raw)

Score, not a recommendation.

Total bought$22.0M11 Form 4 purchases
Distinct insiders7open-market buyers
Insiders' average price$21.36+22.4% to the latest close
Cluster window2026-10-21 → 2026-10-28active

Price and insider purchases

Live chart from Yahoo Finance, loaded through this server; our daily closes when it is unavailable.

Loading price history…

How the score adds up

How each input is counted →
Points each input adds to the score, and how much of the points it could give it has
Input Strength Points
$22.0M bought (counted up to $5.0M)The dollars the insiders bought, a purchase reported jointly counted once, counted from $131. Each tenfold adds 12.4 points, up to $5.0M; more adds nothing. The bar is empty at $10.0K and full at $5.0M. 100% +57
7 distinct insidersHow many different insiders bought. Each extra insider adds less than the one before (the points follow the log of the count: 4.3 per doubling). The bar is full at 10 insiders. 85% +12
No CEO among the buyersWhether the chief executive is among the buyers: 10.6 points when yes. 0% +0
Stock 44% below its 1-year high (counted up to 30%)How far the stock had fallen from its highest close of the past year, at the close before the buying. Every 10% of fall adds 1.9 points. A fall beyond 30% adds nothing more. The bar is full at a 30% fall. 100% +6
7 days from first to last purchaseDays between the first and the last purchase. Each day takes off 0.11 points: buying close together keeps more. The bar is empty at 60 days. 88% -1
Routine or plan purchases: 0% of the dollarsThe share of the dollars in routine or plan purchases (a Rule 10b5-1 plan, dividend reinvestment, a regular cadence). All of it routine would take off 5.6 points. 100% +0
Largest buyer: Ignelzi Troy A. (CFO), 92% of the dollarsThe share of the dollars bought by the largest buyer. Buying spread evenly keeps the points; one buyer paying for everything takes off 12.7. 9% -12
Match scoreA score from 0 to 100 worked out from the dollars bought, the number of insiders, whether a CEO bought, how far the stock had fallen, how spread out the purchases were and how much came from one buyer. Its weights were calibrated on past clusters. It is the default ranking of the lists and it decides which clusters get the AI review. It describes the buying; it is not a forecast.62
AI adjustmentPoints added or taken off by a language model that reads the SEC filings and recent news about the cluster and classifies the buying (for example open market, plan or offering). It can be wrong, it is shown as its own line, and it is never used in past results.-5
Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation.57

Why are they buying?

AI · mixed · catalyst credible · partial

Six insiders (the CFO and five directors) likely bought $1.66M of RAPP stock on October 21-23 because shares had fallen 25.9% over 21 days and sat 44.1% below their 1-year high around the October 20 Phase 2 bipolar mania readout. On October 28, director James Healy's affiliated funds purchased $20.36M at exactly $21.00 per share, matching the date and $21.00 pricing of the company's October 28-30 equity offering and concurrent private placement, though the Form 4 does not explicitly state offering participation.

Three directors initiated new positions and the other four buyers increased existing stakes by 40% to 86%, with none of the seven having sold shares in the prior three years and $0 in non-plan insider sales over the past 90 days. Following the late-October equity and convertible note financing, Rapport Therapeutics reported $815.4M in cash and cash equivalents as of November 3, 2026, providing runway through the end of 2029.

Transactions

11 Form 4 trades · 7 insiders Download CSV Up to 5,000 rows
Purchases in this cluster, grouped by insider, largest first
Date InsiderAn officer or director of a company, or an owner of more than 10% of its shares. The law requires them to report their trades in the company's stock to the SEC. Role Shares Price Value Filing
2026-10-28 HEALY JAMES history of HEALY JAMES's purchases Director 969,480 $21.00 avg $20.4M
2026-10-28 HEALY JAMES 6,395 $21.00 $134.3K SEC filing for HEALY JAMES (opens in a new tab)
2026-10-28 HEALY JAMES 952,380 $21.00 $20.0M SEC filing for HEALY JAMES (opens in a new tab)
2026-10-28 HEALY JAMES 3,772 $21.00 $79.2K SEC filing for HEALY JAMES (opens in a new tab)
2026-10-28 HEALY JAMES 6,933 $21.00 $145.6K SEC filing for HEALY JAMES (opens in a new tab)
2026-10-22 PAUL STEVEN M history of PAUL STEVEN M's purchases Director 35,714 $27.28 $974.3K SEC filing for PAUL STEVEN M (opens in a new tab)
2026-10-22 MARAGANORE JOHN history of MARAGANORE JOHN's purchases Director 9,411 $26.45 avg $248.9K
2026-10-22 MARAGANORE JOHN 1,172 $26.92 $31.5K SEC filing for MARAGANORE JOHN (opens in a new tab)
2026-10-22 MARAGANORE JOHN 8,239 $26.38 $217.3K SEC filing for MARAGANORE JOHN (opens in a new tab)
2026-10-21 Ignelzi Troy A. history of Ignelzi Troy A.'s purchases CFO 5,500 $26.10 $143.6K SEC filing for Ignelzi Troy A. (opens in a new tab)
2026-10-22 Young Wendy B. history of Young Wendy B.'s purchases Director 3,789 $26.39 $100.0K SEC filing for Young Wendy B. (opens in a new tab)
2026-10-22 Silva Paul M history of Silva Paul M's purchases Director 3,680 $27.07 $99.6K SEC filing for Silva Paul M (opens in a new tab)
2026-10-23 Sanchez Ramiro history of Sanchez Ramiro's purchases Director 3,600 $27.35 $98.5K SEC filing for Sanchez Ramiro (opens in a new tab)
Total $22.0M

Other buying runs at RAPP

A buying runPurchases at one company with no pause longer than the cluster rule allows. A long pause ends the run, so one company can have several. ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmarkThe index a stock's return is compared with: a small-cap index for small companies, a large-cap index otherwise. (IWM for small companies, SPY otherwise), from the first open after the buying run became a cluster. Past results, not a forecast.

After this buying run became a cluster, vs benchmark: 21 days –63 days –126 days –

Other insider buying runs at this company, newest first, with the return against the benchmark that followed
Window Insiders Total Score 21 days vs benchmark63 days vs benchmark126 days vs benchmark Status
2025-09-11 → 2025-09-12 3 $1.6M 55 -4.8% (+0.2% raw)+9.3% (+15.0% raw)-0.8% (+2.9% raw) closed